Brought to you by 
Domain Therapeutics brings in €2mm via Series B round
16 Aug 2012
Executive Summary
In what appears to be its Series B round, Domain Therapeutics SA--a French company developing small molecules that target GPCRs--has raised €2mm ($2.45mm) from first-time backers Seventure Partners (contributed €1mm) and SODIV, and returning shareholders Alsace Inter Regio Fonds d'Investissement (AIRFI), IP Growth, Auriga Partners, and the company’s chairman. Domain will use the proceeds to continue the discovery and development of GPCRs using its DTect-All platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Domain Therapeutics brings in €2mm via Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice